Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
